568 related articles for article (PubMed ID: 9408607)
21. Effects of interleukin-2 transduction on the human hepatoma cell lines using retroviral vector.
Kim JH; Gong SJ; Yoo NC; Lee H; Shin DH; Uhm HD; Jeong SJ; Cho JY; Rha SY; Kim YS; Chung HC; Roh JK; Min JS; Kim BS
Oncol Rep; 1999; 6(1):49-54. PubMed ID: 9864400
[TBL] [Abstract][Full Text] [Related]
22. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
[TBL] [Abstract][Full Text] [Related]
23. Constitutive production of IL-2 by human carcinoma cells, expression of IL-2 receptor, and tumor cell growth.
Lin WC; Yasumura S; Suminami Y; Sung MW; Nagashima S; Stanson J; Whiteside TL
J Immunol; 1995 Nov; 155(10):4805-16. PubMed ID: 7594483
[TBL] [Abstract][Full Text] [Related]
24. Multicomponent gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin-7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo activated dendritic cells.
Sharma S; Miller PW; Stolina M; Zhu L; Huang M; Paul RW; Dubinett SM
Gene Ther; 1997 Dec; 4(12):1361-70. PubMed ID: 9472560
[TBL] [Abstract][Full Text] [Related]
25. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression.
Ji L; Fang B; Yen N; Fong K; Minna JD; Roth JA
Cancer Res; 1999 Jul; 59(14):3333-9. PubMed ID: 10416589
[TBL] [Abstract][Full Text] [Related]
26. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
Puri RK; Leland P
Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
[TBL] [Abstract][Full Text] [Related]
27. Human gastric carcinoma transduced with the IL-2 gene: increased sensitivity to immune effector cells in vitro and in vivo.
Nagashima S; Kashii Y; Reichert TE; Suminami Y; Suzuki T; Whiteside TL
Int J Cancer; 1997 Jul; 72(1):174-83. PubMed ID: 9212240
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
29. [Effect of lymphokine-activated killer cells of head and neck tumors in vitro and in nude mice].
Duan DS
Zhonghua Er Bi Yan Hou Ke Za Zhi; 1993; 28(5):281-3, 314. PubMed ID: 8192930
[TBL] [Abstract][Full Text] [Related]
30. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
Peters PM; Ortaldo JR; Shalaby MR; Svedersky LP; Nedwin GE; Bringman TS; Hass PE; Aggarwal BB; Herberman RB; Goeddel DV
J Immunol; 1986 Oct; 137(8):2592-8. PubMed ID: 3760569
[TBL] [Abstract][Full Text] [Related]
31. [Combined interleukin-2 and herpes simplex virus thymidine kinase gene therapy for head and neck squamous cell carcinoma].
Liu S; Liang C; Yang H; Xian J
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Dec; 36(6):426-9. PubMed ID: 12761956
[TBL] [Abstract][Full Text] [Related]
32. Role of interleukin (IL)-2 and IL-15 in the tumour progression of a melanoma cell line MELP, derived from an IL-2 progressor patient.
Doucet C; Meazza R; Pottin-Clemenceau C; Scudeletti M; Brouty-Boye D; Ferrini S; Alileche A; Taoufik Y; Jasmin C; Azzarone B; Indiveri F
Melanoma Res; 1997 Aug; 7 Suppl 2():S7-17. PubMed ID: 9578412
[TBL] [Abstract][Full Text] [Related]
33. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines.
Heo DS; Snyderman C; Gollin SM; Pan S; Walker E; Deka R; Barnes EL; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1989 Sep; 49(18):5167-75. PubMed ID: 2766286
[TBL] [Abstract][Full Text] [Related]
34. TGF-alpha antisense gene therapy inhibits head and neck squamous cell carcinoma growth in vivo.
Endo S; Zeng Q; Burke NA; He Y; Melhem MF; Watkins SF; Lango MN; Drenning SD; Huang L; Rubin Grandis J
Gene Ther; 2000 Nov; 7(22):1906-14. PubMed ID: 11127578
[TBL] [Abstract][Full Text] [Related]
35. Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
Mol Ther; 2006 Jan; 13(1):183-93. PubMed ID: 16125469
[TBL] [Abstract][Full Text] [Related]
36. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
Hess SD; Egilmez NK; Shiroko J; Bankert RB
Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
[TBL] [Abstract][Full Text] [Related]
37. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines.
Posner MR; Cavacini LA; Upton MP; Tillman KC; Gornstein ER; Norris CM
Clin Cancer Res; 1999 Aug; 5(8):2261-70. PubMed ID: 10473114
[TBL] [Abstract][Full Text] [Related]
38. Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.
Yamada H; Matsumoto S; Matsumoto T; Yamada T; Yamashita U
J Urol; 2000 Aug; 164(2):526-31. PubMed ID: 10893638
[TBL] [Abstract][Full Text] [Related]
39. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
[TBL] [Abstract][Full Text] [Related]
40. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants.
Allione A; Consalvo M; Nanni P; Lollini PL; Cavallo F; Giovarelli M; Forni M; Gulino A; Colombo MP; Dellabona P
Cancer Res; 1994 Dec; 54(23):6022-6. PubMed ID: 7954438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
